Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Кафедра психиатрии ФУВ РГМУ, Москва
Список исп. литературыСкрыть список 1. Аведисова А.С. Венлафаксин (велаксин): результаты международных исследований антидепрессанта III поколения. Психиатр. и психофармакотер. 2006; 2: 2–7. 2. Барденштейн Л.М. Венлафаксин (велаксин) – современный антидепрессант двойного действия. Психиатрия. 2005; 6: 62–-5. 3. Васюк Ю.А., Довженко Т.В., Школьник Е.Л., Ющук Е.В. Депрессия и хроническая сердечная недостаточность при сердечно-сосудистых заболеваниях. М., 2008. 4. Вейн А.М., Вознесенская Т.Г., Голубев В.Л., Дюкова Г.М. Депрессия в неврологической практике. М., 2007. 5. ВОЗ. Доклад о состоянии здравоохранения в мире. М., 2002. 6. Вознесенская Т.Г. Депрессия в неврологии. 2001; VII: 2. 7. Гехт А.Б., Боголепова А.Н., Сорокина И.Б. Особенности депрессивного синдрома у больных, перенесших ишемический инсульт. Журн. неврол. и психиатр. 2001; 2: 35–9. 8. Гусев Е.И., Гехт А.Б., Боголепов А.Н., Сорокина И.Б. Особенности депрессивного синдрома у больных, перенесших ишемический инсульт. Инсульт. 2001; 3: 28–31. 9. Гусев Е.И., Гехт А.Б. Реабилитация в неврологии. Учебное пособие. М., 2000. 10. Данилов А.Б., Раймкулова О.К. Лечение болевых синдромов антидепрессантом венлафаксином. Журн. неврол. и психиатр. 2009; 1: 76–9. 11. Довженко Т.В. Расстройства депрессивного спектра с кардиалгическим синдромом у больных сердечно-сосудистыми заболеваниями (клиника, диагностика, терапия). Автореф. дис. … докт. мед. наук. М., 2008. 12. Дробижев М.Ю. Селективные ингибиторы обратного захвата серотонина и норадреналина. Больше различий, чем сходства. Психиатр. и психофармакотер. 2005; 4. 13. Дробижев М.Ю., Добровольский А.В., Долецкий А.А. Кардиологические и психопатологические аспекты безопасности комбинированной кардио- и психотропной терапии. Психиатр. и психофармакотер. 2005; 3: 132–7. 14. Дущанова Г.А., Абасова Г.Б., Бейсетаева Ж.О., Шин М.Г. Реабилитация больных с постинсультной депрессией. Медицина. 2007; 8. 15. Железнова М.В. Венлаксор (венлафаксин) в терапии депрессивных расстройств (опыт применения в амбулаторной и клинической практике). Психиатр. и психофармакотер. 2010; 2: 3–6. 16. Занен П. Применение Венлафаксина в терапии психических расстройств. Соц. и клин. психиатр. 2007; 1: 67–71. 17. Иванов М.В., Банщиков Ф.Р., Кильдеев В.В. Опыт применения эфевелона при лечении тревожно-депрессивных расстройств. Психиатр. и психофармакотер. 2006; 6: 24–7. 18. Иванов С.В. Соматоформные расстройства (органные неврозы): эпидемиология, коморбидные психосоматические соотношения, терапия. Дис. … докт. мед. наук. М., 2002. 19. Иванов С.В., Шафигуллин М.Р., Сгилиди И.С. и др. Эфевелон (венлафаксин) в терапии депрессивных расстройств у пациентов с онкологическими заболеваниями. Психич. расстройства в общ. мед. 2007; 3: 15–8. 20. Камчатнов П. Возможность применения Венлафаксина при невропатическом болевом синдроме. Врач. 2007; 3: 51–4. 21. Канаева Л.С., Захарова К.В., Григорова О.В. Качество ремиссии при применении препарата Велафакс у пациентов с непсихотическими депрессивными расстройствами. Психиатр. и психофармакотер. 2007; 3: 33–7. 22. Левин Я.И. Венлафаксин (Велафакс) в терапии хронических болей в спине. Врач. 2007; 10: 62–6. 23. Маколкин В.И., Абакумов С.А., Сапожников А.А. Нейроциркуляторная дистония в терапевтической практике. М., 1995. 24. Медведев В.Э., Албантова К.А., Григорьева К.В., Сыркин А.Л. Психопатологические и патохарактерологические характеристики пациентов с кардионеврозом (нейроциркуляторная дистония). Психич. расстройства в общ. мед. 2008; 2: 18–21. 25. Медведев В.Э., Добровольский А.В. Лечение депрессий у больных сердечно-сосудистыми заболеваниями. Опыт применения Велаксина. Психиатр. и психофармакотер. 2007; 3: 23–7. 26. Медведев В.Э., Добровольский А.В. Эфевелон в терапии депрессивных расстройств у пациентов кардиологического стационара. Психич. расстройства в общ. мед. 2007; 4: 30–4. 27. Мищенко В.Н. Постинсультные состояния у больных с ишемическими нарушениями мозгового кровообращения. Дис. … канд. мед. наук. Харьков, 2006. 28. Мищенко Т.С., Песоцкая Е.В. Опыт применения препарата Венлаксор в лечении постинсультных депрессий. Укр. вестн. психоневрол. 2010; 1 (62): 19–25. 29. Морозов Б.Б. Актуальные проблемы патофизиологии (избранные лекции). М.: Медицина, 2001. 30. Подкорытов В.С., Чайка Ю.Ю. Депрессии. Современная терапия. Харьков: Торнадо, 2003. 31. Решетова Т.В., Жигалова Т.Н. Новые возможности применения Венлаксора (венлафаксина) для лечения депрессий в общей врачебной практике. Фарматека. Кардиология. Неврология. Ревматология. 2007; 19 (153): 53–6. 32. Савина М.А. Постинсультная депрессия. Журн. неврол. и психиатр. 2005; 7: 67–74. 33. Смулевич А.Б. Депрессии в общей медицине. М., 2001. 34. Смулевич А.Б., Сыркин А.Л. и др. Психокардиология. М., 2005. 35. Табеева Г.Р., Вейн А.М. Фармакотерапия депрессии. Психиатр. и психофармакотер. 2000; 1: 12–9. 36. Тимофеева Т.Н., Шальнова С.А., Константинов В.В. и др. Распространенность факторов, влияющих на прогноз больных артериальной гипертонией, и оценка общего сердечно-сосудистого риска. Журн. Кардиоваск. тер. и проф. 2005; 6 (1): 5–9. 37. Чахава К.О. Применение венлафаксина (Эфевелон) при депрессивных расстройствах у больных с хроническим болевым синдромом. Рус. мед. журн. 2007; 24: 1867–72. 38. Adelman L, Seggern R, Mannix L. Venlafaxine XR for Prophylaxis of Migrain and Tension-type Headache. Headache. 2000; 40: 572–80. 39. Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache. 2000; 40: 572–80. 40. Amsterdam J. Efficacy and Safety of Venlafaxine in the Treatment of Bipolar II Major Depressive Episode. J Clin Psychopharmac 1998; 18 (5): 414–7. 41. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harvard Rev Psychiat 2000; 7: 257–7. 42. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 10: 2433–45. 43. Barkin RL, Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am J Ther 2000; 7: 31–47. 44. Begré S, Traber M, Gerber M, von Känel R. Regional origin and decrease of pain in patients with depressive symptoms under treatment with venlafaxine. Soc Psychiat Epidemiol 2010; 45: 17–24. 45. Benkert O, Gruender G, Wetzel H et al. A randomised, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiat Res 1996; 30: 441–51. 46. Blumer D, Heibronn M. Chronic pain as a variant of depressive disease. The pain–prone disorder. J Nerv Mental Disorders 1982; 170: 381–406. 47. Bradley RH, Barkin RL, Jerome J et al. Efficacy of venlafaxine for the long-term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003; 10: 318–23. 48. Briiey M. The logical evolution towards dual action antidepressants. Drugs in Focus 2001; 3: 5–10. 49. Buckley NA, McManus PR. Fatal toxicity of serotonergic and other antidepressant drugs: analysis of UK mortality data. BMJ 2002; 325: 1332–3. 50. Burnett F, Dinan T. Venlafaxine. Pharmacology and Therapeutic Potential in the Treatment of Depression. Human Psychopharmacol 1998; 13: 153–62. 51. Cohen LS, Soares CN, Lyster A et al. Эффективность и переносимость венлафаксина в терапии дисфорического предменструального синдрома: гибкие дозы, терапия перед началом менструального цикла. J Clin Psychopharmacol 2004; 24 (5): 540–3. 52. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled midticenter study. J Affective Disorders 1990; 18: 289–99. 53. Damian D, van der Wee N, van Megen H et al. Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Cоmpulsive Disorders. J Clin Psychopharmacol 2003; 23 (6): 568–75. 54. Davis JL, Smith RL. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules. Diabetes Care 1999; 22: 1909–10. 55. de Montigny C, Silverstone PH, Debonnel G et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999; 19 (5): 401–6. 56. Diamond S. Efficacy and safety profile of venlafaxine in chronic headache. Headache Q Curr Treat Res 1995; 6: 212–4. 57. Durand J, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 2005; 16 (5): 587–91. 58. Dwight MM, Arnold LM, O’Brien H et al. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998; 39: 14–7. 59. Enlsuah R, Rudolph R, Derivan R, Rickels K. A low relapse rate confirms the long term efficacy ofvenlafaxine in the treatment of major depression. 32 nd Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, Hawaii 1993; 11–17: 192. 60. Entsuah AR et al. Response and remission rates in different subpopulations with major depressive disorder administered Venlafaxine, selective serotonin reuptake, or placebo. J Clin Psychiatry 2001; 62 (11): 869–77. 61. Erdemoglu AK. Effectiveness of venlafaxine in symptomatic treatment of diabetic neuropathy. Ann Neurol 2002; 52: 64. 62. Fava M, Mallinckrodt CH, Detke MJ et al. The effect duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission attest? J Clin Psychiatry 2004; 65 (4): 521–30. 63. Fukuda T, Nishida Y, Zhou Q et al. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000; 56 (2): 175–80. 64. Galvez R, Caballero J, Atero M еt al. Venlafaxine extended release for the treatment of chronic pain. A series of 50 cases. Actas Esp Psiquiatr 2004; 32 (2): 92–7. 65. Garcia-Portilla MP, Bascaran MT, Saiz PA et al. Effectiveness of venlafaxine in the treatment of alcohol dependence with comorbid depression. Actas Esp Psiquiat 2005; 33 (1): 41–5. 66. Gasto C, Navarro V, Marcos T et al. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 2003; 23 (1): 21–6. 67. Gorman J, Laszio A. Efficacy of Venlafaxine in mixed Depression-Anxiety States. Depression and Anxiety 2000: 12 (1): 77–80. 68. Grothe D, Scheckner B, Albano D. Treatment of Pain Syndromes with Venlafaxine. Pharmacolher 2004; 24 (5): 621–39. 69. Guldiken S, Guldiken B, Arikan E. Complete relief of pain in acute painful diabetic neuropathy of rapid glycaemic control (insulin neuritis) with venlafaxine HCL. Diabetes Nutr Metab 2004; 17 (4): 247–9. 70. Gultekin H, Ahmedov V. Role of the opioidergic system and nitric oxide in the analgesic effect of venlafaxine. Yakugaku Zasshi 2006; 126 (2): 117–21. 71. Gump BB, Matthews KA, Eberly LE, Chang YF. Depressive symptoms and mortality in men: results from the Multiple Risk Factor Intervention Trial Stroke 2005; 36: 98–102. 72. Gutierrez MA, Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. Clin Ther 2003; 25 (8): 2138–54. 73. Haanpää ML, Gourlay GK, Kent JL et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc 2010; 85 (3 Suppl): 15–25. 74. Hackelt D, Agniar L, Rudolph R. Venlafaxine prevents recurrence of depression (Poster presentation) Presenter at the 1 Ith Congress of the European College of Neuropsychopharmacology, Paris, France, 1998. 75. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007; 64 (2): 192–7. 76. Hunter AM, Leuchter AF, Morgan ML et al. Neurophysiologic correlates of the Side Effects in Normal Subjects Randomized to Venlafaxine or Placebo. Neuropsychopharmacol 2005; 30 (4): 792–9. 77. Judd LL, Rapoport MH. Economics of depression and cost-benefit comparisons of selective serotonin reuptake inhibitors and tricyclic antidepressants. Depression 1995; 2: 173–7. 78. Judge R, Wagner B. Once-daily venlafaxine XR compared with fluoxetine in outpatient with depression and anxiety. J Clin Psychiat 1999; 60: 795–6. 79. Kathpal GS. Role of SSRIs in the management of migraine. Headache Q Curr Treat Res 1998; 9: 265–6. 80. Khan A, Upton GV, Rudolph R et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol 1998; 18 (1): 19–25. 81. Keefe FJ, Lefebvre J. Pain behavior concepts: Controversies, current status and future directions directions. In: G.Gebhart, D.L.Hammond, T.S.Jensen. Proceedings of the VII Word Congress of Pain. New York: Elsevier 1994: 127–148. 82. Kelsey J. Efficacy, Safety, Tolerability of Venlafaxine XR in GAD. Depres Anxiety 2000; 12 (1): 81–4. 83. Kiayias JA, Vlachou ED, Lakka-Papadodima E. Venlafaxine HCl in the treatment of painful peripheral diabetic neuropathy. Diabetes Care 2000; 23: 699. 84. Krishnan KR, France RD, Pelton S et al. Chronic pain and depression. I. Classification of depression in chronic low back pain patients. Pain 1985; 22: 279–87. 85. Krishnan KR, France RD, Pelton S et al. Chronic pain and depression. II. Symptoms of anxiety in chronic low back pain patients and their relationship to subtypes of depression. Pain 1985; 22: 289–94. 86. Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch Intern Med 1993; 153: 2474–80. 87. Kunz N, Goli V, Entsuah R et al. Diabetic neuropathic pain management with venlafaxine extended release. Eur Neuropsychopharmaco 2000; 10: 389. 88. Lecable P, Letzelter J-M, Lichtblau Е et al. An open label study of the clinical acceptability ofvenlafaxine for depression. Primary Care Psychiatry 1995; 1: 119–26. 89. Lindsay PG, Wycoff M. The depression–pain syndrome and the response to antidepressants. Psychosomatics 1981; 22: 571–7. 90. Lithner F. Venlafaxine in treatment of severe painful peripheral diabetic neuropathy. Diabetes Care 2000; 23: 1710–1. 91. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiat Neurosci 2001; 26: 30–6. 92. Lopez-lbor J, Guelfi JD, Pletan Х et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Internal Clin Psychopharmacol 1996; 11 (Suppt. 4): 41–6. 93. Lopez AA, Bragg J, Young E еt al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in United States and Europe. Kidney Int 2002; 62 (1): 199–207. 94. Magni G. The use of antidepressants in the treatment of chronic pain: a review of the current evidence. Drugs 1991; 42: 730–48. 95. Mattia C, Paoletti F, Coluzzi F, Boanelli A. New antidepressants in the treatment of neuropathic pain A review. Minerva Anestesiol 2002; 68 (3):105–14. 96. Mazeh D, Shahal B, Saraf R et al. Venlafaxine for the Treatment of Depressive Episode During the Course of Schizophrenia. J Clin Psychopharmacol 2004; 24 (6): 653–5. 97. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety doses ofvenlafaxine in a dose response study. Psychopharmacol Bull 1993: 29: 169–74. 98. Meoni P. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiat 2001; 62: 888–93. 99. Miller A, Rabe-Jabłońska J. The effectiveness of antidepressants in the treatment of chronic non-cancer pain – a review. Psychiatr Pol 2005; 39 (1): 21–32. 100. Mitchell PB, Schweitzer I, Burrows G et al. Efficacy of Venlafaxine and Predictors of Response in a Prospective Open Research. J Clin Psychopharmacol 2000; 20 (4): 483–7. 101. Mohr P, Bitter I, Svestka J et al. Management of depression in the presence of pain symptoms Psychiatr Danub 2010; 22 (1): 4–13. 102. Montgomery SA. Rapid onset of action of venlafaxine. Int Clin Psychopharmacol 1995; 10 (2). 103. Montgomery SA, Mahe V, Haudiquet V et al. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol 2002; 22 (6): 561–7. 104. Nayer A De, Geerts S, Ruelens L et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002; 5 (2): 115–20. 105. Ninan Ph. Use of Venlafaxine in other Psychiatryc Disorders. Depres Anxiety 2000; 12 (1): 90–4. 106. O\'Hanlon JF, Robbe HWJ, Vermeeren A et al. Venlafaxine\'s effects on healthy volunteers\' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 1998; 18 (3): 212–21. 107. Ohayon M, Schatzberg A. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiat 2003; 60: 39–47. 108. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic nonmalignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992; 49: 205–19. 109. Ozyalcin SN, Talu GK, Kiziltan E et al., The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45 (2): 144–52. 110. Paolucci S, Antonucci G, Grasso MG et al. Post-stroke depression, antidepressant treatment and rehabilitation results: a case-control study. Cerebrovasc Dis 2001; 12: 264–71. 111. Pernia A, Mico JA, Calderon E, Torres LM. Venlafaxine for the treatment of neuropathic pain. J Pain Symptom Manage 2000; 19: 408–10. 112. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistent depression. Double-blind, randomised comparison. Br J Psychiat 1999; 175: 12–6. 113. Pollack M, Meoni P, Otto MW et al. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol 2003; 23 (3): 250–9. 114. Preskorn SH Applied Clinical Psychopharmucology. J Practic Psychiatry Beh Health 1999; 7: 224–8. 115. Reuben S, Lurie S, Deluca P, Charles GS. Efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. Presented at the 27th meeting of the American Society of Regional Anesthesia and Pain Medicine, Chicago, IL 2002. 116. Rowbotham M, Goli V, Kunz N, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110 (3): 697–706. 117. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003; 54 (3): 227–40. 118. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharm 1996; 16 (3): 54–61. 119. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 1998; 18 (2): 136–44. 120. Rudolph RL, Feighner J, Rickets К. A double blind, randomised, placebo-controlled trial of venlafaxin in outpatients with major depression. J Clin Psychiat 2010 (in press). 121. Ruo B, Rumsfeld JS, Hlatky MA et al. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003; 290 (2): 215–21. 122. Saarto T, Wiffen P. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005; 3: CD005454. 123. Saletu B, Grunberger J, Andererm С et al. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Brit J Clin Pharmacol 1992; 33: 589–601. 124. Sanders SH. Behavior assessment of clinical pain: appraisal of current status. New York: Academic Press, 1979; 8: 310. 125. Schreiber S, Backer M, Pick C. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 1999; 273 (2): 85–8. 126. Schweitzer I, Burrows G, Tuckwell V et al. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol 2001; 21 (2): 185–9. 127. Schweizer E, Weise C, Clary С et al. Placebo controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991; 11: 233–6. 128. Sellers EM, Ball SE, Cheung SW et al. Inhibition by venlafaxine (VF) and other 5HT reuptake inhibitors of the polymorphic enzyme CYP2D6. 22nd Annual Meeting of the American College of Neuropsychopharmacology. Honolulu 1993; 13–17: 163. 129. Sindrup SH, Bach FW, Madsen C et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60: 1284–9. 130. Shrivastava R, Cohn C, Crowder J et al. Long term safety and clinical acceptability ofvenlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994; 14: 322–9. 131. Songer DA, Schulte H. Venlafaxine for the treatment of chronic pain. Am J Psychiat 1996; 153: 737. 132. Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother 2001; 35: 557–9. 133. Strik JJ, Lousberga R, Cheriexb EC, Honiga A. One year cumulative incidence of depression following myocardial infarction and impact on cardiac outcome. J Psychosomatic Res 2004; 56: 59–66. 134. Tasmuth T, Haertel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain London 2002; 6: 17–24. 135. Taylor K, Rowbotham MC. Venlafaxine hydrochloride and chronic pain. Western J Med 1996; 165: 147–8. 136. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008; 118 (6): 434–42. 137. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiat 1998; 59: 502–8. 138. Thase M, Friedman M, Howland R. Venlafaxine and treatment-resistent depression. Depression Anxiety 2000; 12 (1): 55–62. 139. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiat 2001; 178: 234–41. 140. Tylee A, Beumonl G, Bowden M, Reynolds A. A double blind, randomised, 12 week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry 1997; 3: 51–8. 141. Thomson P.D.R. Physicians Desk Reference. 58th ed. 2004: 3413–24. 142. Verma S, Estanislao L, Simpson D. HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs 2005; 19: 325–34. 143. Von Knorring L, Perris C, Eisemann M et al. Pain as a symptom in depressive disorder. I. Relationship to diagnostic subgroup and depressive symtomatology. Pain 1983; 15: 19–26. 144. Von Knorring L. The Experience of Pain in Patients with Depressive Disorders. A clinical and Experimental Study. Umea University Medical Dissertation, New Series No 2, Umea University, 1975. 145. Wang СР, Howell SR, Scatina J, Sisenwine SF. The disposition ofvenlafaxine enanto-mers in dogs, rats, and humans receiving venlafaxine. Chiralily 1992; 4: 84–90. 146. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997; 14: 2–31. 147. Wood PH. Applications of the International Classification of Diseases. World Health Stat Q 1990; 43 (4): 263–8. 148. Yilmaz M, Kadiroglu A, Kara I, Dikici S. Venlafaxine in the treatment of painful peripheral diabetic neuropathy in a uremic patient undergoing hemodialysis. Med Gen Med 2002; 4 (3): 23–8. 149. Yucel A, Ozyalcin S, Koknel Talu G et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain 2005; 9 (4): 407–16. 150. Zimmer B, Kant R, Zeiller D et al. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs. old patients with comorbid medical disorders. Int J Psychiat Med 1997; 27 (4): 353–64.